QTP XR 200 - tablet Quetiapine - 200mg 10 Tablet(s) / Strip Square Pharmaceuticals PLC. Introduction: QTP XR 200 is a prescription medicine used in the treatment of schizophrenia (a mental disorder that can result in hallucinations or delusions and also adversely affects a person’s ability to think and behave) and mania. It is also used to treat bipolar disorders. QTP XR 200 may be taken with or without food. However, it is advised to take it at the same time each day as this helps to maintain a consistent level of medicine in the body. Take this in the dose and duration as advised by your doctor and if you have missed a dose, take... Uses of QTP XR 200: SchizophreniaMania Side effects of QTP XR 200: Akathisia (inability to stay still)Decreased haemoglobin level in bloodDizzinessDystonia (involuntary muscle contractions)HeadacheIncreased triglyceride level in bloodParkinsonismSleepinessWeight gain How to use QTP XR 200: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. QTP XR 200 may be taken with or without food, but it is better to take it at a fixed time. How QTP XR 200 works: QTP XR 200 is an atypical antipsychotic. It works by modulating the action of certain chemical messengers in the brain that affect thoughts. Indication: Schizophrenia, Bipolar disorder, Major depressive disorder Administration: Extended-release: Should be taken on an empty stomach. Take w/o food or w/ a light meal. Swallow whole, do not chew/crush. May be taken with or without food. Adult Dose: Oral Schizophrenia Immediate release Day 1: 50 mg/day PO divided q12hr Days 2-3: Dose increased daily in increments of 25-50 mg q8-12hr to 300-400 mg by day 4; further adjustments can be made in increments of 25-50 mg q12hr at intervals >2 days Dosage range: 150-750 mg/day Extended release Day 1: 300 mg/day PO; subsequently, may be increased by up to 300 mg/day at intervals >1 day Maintenance (monotherapy): 400-800 mg/day Patients who have discontinued therapy for >1 week should have their dose retitrated following initiation of therapy; patients may reinitiate at their previous maintenance dose if discontinued therapy <1... Child Dose: Schizophrenia Immediate release Day 1: 50 mg/day PO divided q12hr Days 2-3: Dose increased daily in increments of 25-50 mg q8-12hr to 300-400 mg by day 4; further adjustments can be made in increments of 25-50 mg q12hr at intervals >2 days Dosage range: 150-750 mg/day Extended release Day 1: 300 mg/day PO; subsequently, may be increased by up to 300 mg/day at intervals >1 day Maintenance (monotherapy): 400-800 mg/day Patients who have discontinued therapy for >1 week should have their dose retitrated following initiation of therapy; patients may reinitiate at their previous maintenance dose if discontinued therapy <1 week... Contraindication: Quetiapine is contraindicated in individuals with a known hypersensitivity to this medication or any of its ingredients. Severe CNS depression, bone marrow suppression, coma. Mode of Action: Quetiapine is an antagonist at multiple neurotransmitter receptors in the brain: Serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1 and adrenergic a1 and a2 receptors. It is used in the treatment of schizophrenia and bipolar disorder. Precaution: Patient w/ CV and cerebrovascular disease, conditions predisposing to hypotension, history of seizures or conditions that lower the seizure threshold, conditions that may increase risk of QT prolongation. Avoid abrupt withdrawal. Elderly w/ dementia-related psychosis. Hepatic or renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause somnolence and impair judgement, thinking or motor skills, if affected, avoid driving, operating machinery or performing hazardous tasks. Monitoring Parameters Closely monitor for worsening of glucose control in patients w/ pre-existing DM. Monitor for possible worsening of depression, suicidal thoughts or unusual changes in behaviour. Measure BP at the beginning of, and... Side Effect: >10% Dizziness (1-18%),Fatigue (3-14%),Extrapyramidal symptoms (1-13%),Increased diastolic blood pressure (41%),Increased triglycerides (8-22%),Increased total cholesterol (7-18%),Increased appetite (2-12%),Constipation (6-11%),Dry mouth (9-44%),Headache (7-21),Somnolence (18-57%) 1-10% Abdominal pain (4-7%; dose related),Dyspepsia (2-7%; dose related,Tremor (2-8%),Back pain (3-5%),Postural hypotension (2-7%),Tachycardia (1-6%),Pharyngitis (4-6%),Rhinitis (3-4%),Rash (4%),Blurred vision (1-4%),Arthralgia (1-4%),Myalgia (2%),Neck pain (2%),Dyskinesia (4%),Neutropenia (2%),Hemorrhage (1%) < 1% Priapism,Cardiomyopathy, myocarditis,QTc prolongation,Night mares,Pancreatitis,Rhabdomyolysis,Palpitation,Leukocytosis,Epistaxis,Exfoliative dermatitis Interaction: Increased risk of drowsiness and postural hypotension when used with alcohol. CYP3A4 inducers eg. phenytoin and carbamazepine may decrease plasma levels of quetiapine while CYP3A4 inhibitors eg. ketoconazole and erythromycin may increase its plasma levels.